Zoetis Inc. (ZTS) is a Biotechnology: Pharmaceutical Preparations company listed on NYSE. In the last 30 days Quantisnow tracked 18 wire items for ZTS, including 9 insider trades, 3 SEC filings and 2 analyst ratings. The most recent was published Nov 10, 2026.
ZTS rankings
Financial highlights
Full financials- Revenue, TTM
- $9.49B
- Revenue growth
- +0.9%
- Net income, TTM
- $2.51B
- Net margin
- 26.4%
- Free cash flow, TTM
- $2.23B
- Cash
- $1.33B
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks62-56%
2026-05-172026-11-08
Mix2890d
- Insider13(46%)
- Other6(21%)
- SEC Filings4(14%)
- Earnings2(7%)
- Analyst2(7%)
- Dividends1(4%)
Activity · 52 weeks18370 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- PRZoetis to Participate in the Jefferies Global Healthcare Conference in LondonZoetis Inc. (NYSE:ZTS) today announced that Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Monday, November 16, 2026 at 2 p.m. GMT. Interested parties can access the live webcast of the presentation by visiting https://investor.zoetis.com/events-presentations. A replay will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer way
- SECSEC Form 10-Q filed by Zoetis Inc.10-Q - Zoetis Inc. (0001555280) (Filer)
- SECZoetis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Zoetis Inc. (0001555280) (Filer)
- PRZoetis Announces Third Quarter 2026 Results; Highlights Progress Advancing Innovation Across Diversified Portfolio and Narrows Full Year 2026 Revenue Guidance, Raises Full Year 2026 Adjusted EPS GuidanceThird Quarter 2026 Highlights Revenue: $2.4 billion, decreased 1% reported and organic operational1 U.S. segment revenue: $1.2 billion, decreased 6% reported and organic operational International segment revenue: $1.1 billion, increased 4% reported and organic operational basis Net Income: $591 million, decreased 18% reported Adjusted net income: $720 million, decreased 5% reported and 7% organic operational Diluted EPS: $1.44, decreased 12% reported Adjusted diluted EPS: $1.75, increased 3% reported and 1% organic operational Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today reported its financial results for the third quarter of 2026. "Ou
- INSIDERDirector Stetter Mark was granted 6 phantom stock units (SEC Form 4)4 - Zoetis Inc. (0001555280) (Issuer)
- PRZoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection TreatmentConvenia RTU for Dogs can provide up to 14 days of antibiotic treatment of susceptible bacterial skin infections in dogs in a single injection by a veterinary professional Pyoderma – a bacterial skin infection—is one of the top 5 reasons for vet visits for dogs.1 Administration at the veterinary clinic helps dog owners avoid the day-to-day challenge of giving oral antibiotics at home and reduces the risk of missed or irregular doses. Higher concentration of an antibacterial agent can deliver the same dose of treatment in a smaller volume, helping make single-injection treatment more practical for dogs of all sizes. Zoetis Inc. (NYSE:ZTS) today announced that the U.S. Food and Dr
- ANALYSTZoetis downgraded by Jefferies with a new price targetJefferies downgraded Zoetis from Buy to Hold and set a new price target of $83.00
- ANALYSTGoldman initiated coverage on Zoetis with a new price targetGoldman initiated coverage of Zoetis with a rating of Neutral and set a new price target of $74.00
- INSIDERSEC Form 4 filed by Zoetis Inc.4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by Zoetis Inc.4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by Zoetis Inc.4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by Zoetis Inc.4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by Zoetis Inc.4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by Zoetis Inc.4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by Zoetis Inc.4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by Zoetis Inc.4 - Zoetis Inc. (0001555280) (Issuer)
- SECSEC Form 8-K filed by Zoetis Inc.8-K - Zoetis Inc. (0001555280) (Filer)
- PRZoetis Appoints Iris Knobloch to its Board of DirectorsKnobloch brings deep expertise in consumer strategy, digital transformation, international leadership, and global board experience to the Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the appointment of Iris Knobloch to its Board of Directors, effective as of December 1, 2026. With decades of experience across global media and consumer businesses, Ms. Knobloch brings a distinct combination of international leadership, proven public company board experience across financial services, hospitality and media, and deep consumer and digital expertise to the Zoetis Board. She currently serves on the boards of Deezer S.A., Lazard, Inc. and Vail Resorts, Inc., and has built a track record of
- SECSEC Form 8-K filed by Zoetis Inc.8-K - Zoetis Inc. (0001555280) (Filer)
- PRZoetis Declares Fourth Quarter 2026 DividendThe Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the fourth quarter of 2026. The dividend will be paid on Tuesday, December 1, 2026, to all holders of record of the Company’s common stock as of the close of business on Friday, October 30, 2026. About Zoetis Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness supporting veterinarians, livestock producers and pet owners in over 100 countries. We integrate deep scientific experti
- PRNew Peer-Reviewed Publication on Laboratory Study That Demonstrated Simparica Trio® Protected 3x More Dogs From Infection With a Resistant Heartworm Isolate Than NexGard® Plus1Findings highlight dose-dependent efficacy of moxidectin in preventing heartworm disease Published Data Demonstrated: Simparica Trio®-treated dogs had significantly lower average heartworm counts than NexGard Plus-treated dogs (P = 0.0316).1 Simparica Trio delivered 99.5% efficacy against macrocyclic lactone (ML)-resistant heartworm isolate, ZoeLA, compared to 98.1% for NexGard Plus.1 Simparica Trio protected more dogs from infection: Adult heartworms were found in just 2/8 (25%) of dogs treated with Simparica Trio, versus 6/8 (75%) of dogs treated with NexGard Plus.1 No detection of circulating heartworm offspring (microfilariae) in Simparica Trio-treated dogs: None of the Si
- INSIDERExecutive Vice President Fuller Julie converted options into 799 shares and covered exercise/tax liability with 274 shares, increasing direct ownership by 49% to 1,588 units (SEC Form 4)4 - Zoetis Inc. (0001555280) (Issuer)
- PRZoetis to Host Webcast and Conference Call on Third Quarter 2026 Financial ResultsZoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, November 5, 2026. Chief Executive Officer Kristin Peck and Executive Vice President, Chief Financial Officer and Chief Operating Officer Jay Saccaro will review third quarter 2026 financial results and respond to questions from financial analysts. Investors and the public may access the live webcast and corresponding slides by visiting the Zoetis website at https://investor.zoetis.com/events-presentations. Pre-registration for the webcast is available beginning today. A replay will be made available on November 5, 2026. About Zoetis Zoetis is the world’s leading animal health company, driven by
- INSIDERSEC Form 4 filed by Director Stetter Mark4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by EVP, CFO & COO Saccaro James4 - Zoetis Inc. (0001555280) (Issuer)
ZTS FAQ
11 questionsWhat does Zoetis Inc. do?
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria...What is the latest news on ZTS?
In the last 30 days Quantisnow tracked 18 wire items for ZTS: 9 insider trades, 3 SEC filings, 2 analyst ratings and 2 press releases and news items. The most recent was published on November 10, 2026.What is ZTS revenue?
Zoetis Inc. (ZTS) reported $9.49B of revenue for the twelve months ended Sep 30, 2026. That is up 0.9% from the year before. Revenue for fiscal 2025 was $9.47B.Is ZTS profitable?
Yes. Zoetis Inc. earned $2.51B in net income for the twelve months ended Sep 30, 2026, a net margin of 26.4%.How much cash and debt does ZTS have?
Zoetis Inc. reported $1.33B in cash and cash equivalents and $9.05B of debt on its most recent balance sheet in SEC filings.Where does ZTS stock trade?
Zoetis Inc. (ZTS) is listed on NYSE.What sector and industry is ZTS in?
Zoetis Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Zoetis Inc. go public?
Zoetis Inc. (ZTS) completed its IPO in 2013.What are analysts saying about ZTS?
Across the last 8 analyst actions on Zoetis Inc., there were 0 upgrades and 5 downgrades. The most recent action was from Jefferies: Hold with a $83.00 price target on 2026-10-20. Recent price targets range from $74.00 to $145.00.What companies are similar to ZTS?
Notable peers in the same industry include AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories), MRK (Merck & Company Inc.), ABBV (AbbVie Inc.). Compare ZTS side-by-side with any of them on Quantisnow.How can I track ZTS on Quantisnow?
Quantisnow aggregates Zoetis Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ZTS to receive live email and push alerts on every new disclosure.